Differential roles of aβ42/40, p-tau231 and p-tau217 for alzheimer’s trial selection and disease monitoring

HIGHLIGHTS

• who: Nicholas J. Ashton from the (UNIVERSITY) have published the paper: Differential roles of Au03b242/40, p-tau231 and p-tau217 for Alzheimeru2019s trial selection and disease monitoring, in the Journal: (JOURNAL) of 24/04/2022
• what: The longitudinal results of this study suggest that plasma p-tau217 is a key biomarker to be used when assessing already banked samples from performed clinical trials, which have evaluated relevant therapies or Nature Medicine | Volume 28 | December 2022 | 2555-2562 lifestyle interventions, to determine whether such treatments affect the development of AD-related pathology.
• future . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.